Current animal models of bladder cancer: Awareness of translatability (Review)

Ding,Jie; Xu,Ding; Pan,Chunwu; Ye,Min; Kang,Jian; Bai,Qiang; Qi,Jun

doi:10.3892/etm.2014.1837

Current animal models of bladder cancer: Awareness of translatability (Review)

Authors:
- Jie Ding
- Ding Xu
- Chunwu Pan
- Min Ye
- Jian Kang
- Qiang Bai
- Jun Qi
View Affiliations

Affiliations: Department of Urology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Yangpu, Shanghai 200092, P.R. China
Published online on: July 11, 2014 https://doi.org/10.3892/etm.2014.1837
Pages: 691-699

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Experimental animal models are crucial in the study of biological behavior and pathological development of cancer, and evaluation of the efficacy of novel therapeutic or preventive agents. A variety of animal models that recapitulate human urothelial cell carcinoma have thus far been established and described, while models generated by novel techniques are emerging. At present a number of reviews on animal models of bladder cancer comprise the introduction of one type of method, as opposed to commenting on and comparing all classifications, with the merits of a certain method being explicit but the shortcomings not fully clarified. Thus the aim of the present study was to provide a summary of the currently available animal models of bladder cancer including transplantable (which could be divided into xenogeneic or syngeneic, heterotopic or orthotopic), carcinogen‑induced and genetically engineered models in order to introduce their materials and methods and compare their merits as well as focus on the weaknesses, difficulties in operation, associated problems and translational potential of the respective models. Findings of these models would provide information for authors and clinicians to select an appropriate model or to judge relevant preclinical study findings. Pertinent detection methods are therefore briefly introduced and compared.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin. 63:11–30. 2013.
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
3	Kroft SH and Oyasu R: Urinary bladder cancer: mechanisms of development and progression. Lab Invest. 71:158–174. 1994.PubMed/NCBI
4	Knowles MA: What we could do now: molecular pathology of bladder cancer. Mol Pathol. 54:215–221. 2001. View Article : Google Scholar : PubMed/NCBI
5	Williams SG and Stein JP: Molecular pathways in bladder cancer. Urol Res. 32:373–385. 2004. View Article : Google Scholar
6	Spiess PE and Czerniak B: Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med. 130:844–852. 2006.PubMed/NCBI
7	Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 5:713–725. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hoffman RM: The three-dimensional question: can clinically relevant tumor drug resistance be measured in vitro? Cancer Metastasis Rev. 13:169–173. 1994. View Article : Google Scholar : PubMed/NCBI
9	Yen WC, Schmittgen T and Au JL: Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. Pharm Res. 13:1887–1891. 1996. View Article : Google Scholar : PubMed/NCBI
10	Fujiyama C, Jones A, Fuggle S, et al: Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion. Br J Cancer. 84:558–564. 2001. View Article : Google Scholar : PubMed/NCBI
11	Booth C, Harnden P, Trejdosiewicz LK, Scriven S, Selby PJ and Southgate J: Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest. 76:843–857. 1997.PubMed/NCBI
12	Sabbagh W, Masters JR, Duffy PG, et al: In vitro assessment of a collagen sponge for engineering urothelial grafts. Br J Urol. 82:888–894. 1998. View Article : Google Scholar : PubMed/NCBI
13	Verbridge SS, Choi NW, Zheng Y, Brooks DJ, Stroock AD and Fischbach C: Oxygen-controlled three-dimensional cultures to analyze tumor angiogenesis. Tissue Eng Part A. 16:2133–2141. 2010. View Article : Google Scholar : PubMed/NCBI
14	Oyasu R: Epithelial tumours of the lower urinary tract in humans and rodents. Food Chem Toxicol. 33:747–755. 1995. View Article : Google Scholar : PubMed/NCBI
15	Lindblad-Toh K: Genome sequencing: three’s company. Nature. 428:475–476. 2004.
16	Russell PJ, Raghavan D, Gregory P, et al: Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res. 46:2035–2040. 1986.PubMed/NCBI
17	Flanagan SP: ‘Nude’, a new hairless gene with pleiotropic effects in the mouse. Genet Res. 8:295–309. 1966.
18	Masters JR, Hepburn PJ, Walker L, et al: Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res. 46:3630–3636. 1986.PubMed/NCBI
19	Günther JH, Jurczok A, Wulf T, et al: Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 59:2834–2837. 1999.
20	Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 17:343–359. 1999. View Article : Google Scholar : PubMed/NCBI
21	Booth C, Harnden P, Selby PJ and Southgate J: Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol. 198:359–368. 2002. View Article : Google Scholar : PubMed/NCBI
22	Reznikoff CA, Belair C, Savelieva E, et al: Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev. 8:2227–2240. 1994. View Article : Google Scholar : PubMed/NCBI
23	Kao C, Wu SQ, Bhatthacharya M, Meisner LF and Reznikoff CA: Losses of 3p, 11p, and 13q in EJ/ras-transformable simian virus 40-immortalized human uroepithelial cells. Genes Chromosomes Cancer. 4:158–168. 1992. View Article : Google Scholar : PubMed/NCBI
24	Harding MA, Arden KC, Gildea JW, et al: Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res. 62:6981–6989. 2002.
25	Gildea JJ, Golden WL, Harding MA and Theodorescu D: Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer. 27:252–263. 2000. View Article : Google Scholar : PubMed/NCBI
26	Cristofalo VJ, Lorenzini A, Allen RG, Torres C and Tresini M: Replicative senescence: a critical review. Mech Ageing Dev. 125:827–848. 2004. View Article : Google Scholar : PubMed/NCBI
27	Zhao L, Zhang ZY and Tong TJ: Systemic aging and replicative senescence: in vivo and in vitro. Sheng Li Ke Xue Jin Zhan. 31:205–210. 2000.(In Chinese).
28	MacLeod RAF, Dirks WG, Matsuo Y, et al: Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer. 83:555–563. 1999.PubMed/NCBI
29	Russell PJ, Raghavan D, Gregory P, et al: Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res. 46:2035–2040. 1986.PubMed/NCBI
30	Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL and McConkey DJ: Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res. 64:4601–4610. 2004. View Article : Google Scholar
31	Inoue K, Slaton JW, Davis DW, et al: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 6:2635–2643. 2000.
32	Pfost B, Seidl C, Autenrieth M, et al: Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 50:1700–1708. 2009. View Article : Google Scholar : PubMed/NCBI
33	Makhlin I, Zhang J, Long CJ, et al: The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int. 108:E84–90. 2011. View Article : Google Scholar : PubMed/NCBI
34	Dinney CP, Fishbeck R, Singh RK, et al: Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol. 154:1532–1538. 1995. View Article : Google Scholar : PubMed/NCBI
35	Soloway MS, Martino C, Hyatt C and Marrone JC: Immunogenicity of N-[-4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer. Natl Cancer Inst Monogr. 293–300. 1978.
36	Soloway MS: Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res. 37:2918–2929. 1977.PubMed/NCBI
37	Summerhayes IC and Franks LM: Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst. 62:1017–1023. 1979.PubMed/NCBI
38	van Moorselaar RJ, Ichikawa T, Schaafsma HE, et al: The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. Urol Res. 21:413–421. 1993.PubMed/NCBI
39	Moltedo B, Faunes F, Haussmann D, et al: Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins. J Urol. 176:2690–2695. 2006. View Article : Google Scholar
40	Bisson JF, Parache RM, Droulle P, Notter D, Vigneron C and Guillemin F: A new method of implanting orthotopic rat bladder tumor for experimental therapies. Int J Cancer. 102:280–285. 2002. View Article : Google Scholar : PubMed/NCBI
41	Hanel EG, Xiao Z, Wong KK, Lee PW, Britten RA and Moore RB: A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy. J Urol. 172:2018–2022. 2004. View Article : Google Scholar : PubMed/NCBI
42	Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H and Lilly M: Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol. 173:604–609. 2005. View Article : Google Scholar : PubMed/NCBI
43	Loskog AS, Fransson ME and Totterman TT: AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res. 11:8816–8821. 2005. View Article : Google Scholar : PubMed/NCBI
44	Kuromatsu I, Matsuo K, Takamura S, et al: Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria. Cancer Gene Ther. 8:483–490. 2001. View Article : Google Scholar : PubMed/NCBI
45	Miyazaki J, Nishiyama H, Yano I, et al: The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res. 31:2065–2071. 2011.PubMed/NCBI
46	Smaldone MC, Gayed BA, Tomaszewski JJ and Gingrich JR: Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva Urol Nefrol. 61:71–89. 2009.PubMed/NCBI
47	Smaldone MC, Gayed BA, Tomaszewski JJ and Gingrich JR: Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva Urol Nefrol. 61:71–89. 2009.PubMed/NCBI
48	Shen ZJ, Wang Y, Ding GQ, Pan CW and Zheng RM: Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits. World J Urol. 25:525–529. 2007.
49	Günther JH, Frambach M, Deinert I, Brandau S, Jocham D and Böhle A: Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49). J Urol. 161:1702–1706. 1999.PubMed/NCBI
50	Reis LO, Ferreira U, Billis A, Cagnon VH and Fávaro WJ: Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer. J Urol. 187:438–445. 2012.PubMed/NCBI
51	Talmadge JE, Singh RK, Fidler IJ and Raz A: Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 170:793–804. 2007. View Article : Google Scholar : PubMed/NCBI
52	Lodillinsky C, Rodriguez V, Vauthay L, Sandes E, Casabé A and Eiján AM: Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer. J Urol. 182:749–755. 2009. View Article : Google Scholar : PubMed/NCBI
53	Black PC and Dinney CP: Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev. 26:623–634. 2007. View Article : Google Scholar : PubMed/NCBI
54	Wilmanns C, Fan D, Obrian C, et al: Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice. Int J Oncol. 3:413–422. 1993.PubMed/NCBI
55	Bibby MC: Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer. 40:852–857. 2004. View Article : Google Scholar : PubMed/NCBI
56	Zhang Z, Xu X, Zhang X, et al: The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer. Acta Oncol. 50:1111–1118. 2011. View Article : Google Scholar : PubMed/NCBI
57	Xiao Z, McCallum TJ, Brown KM, et al: Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer. 81:638–646. 1999. View Article : Google Scholar : PubMed/NCBI
58	Chade DC, Andrade PM, Borra RC, et al: Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. Int Braz J Urol. 34:220–226; discussion 226–229. 2008. View Article : Google Scholar : PubMed/NCBI
59	Jiang F and Zhou XM: A model of orthotopic murine bladder (MBT-2) tumor implants. Urol Res. 25:179–182. 1997. View Article : Google Scholar : PubMed/NCBI
60	Romih R, Jezernik K and Masera A: Uroplakins and cytokeratins in the regenerating rat urothelium after sodium saccharin treatment. Histochem Cell Biol. 109:263–269. 1998. View Article : Google Scholar : PubMed/NCBI
61	Gabriel U, Bolenz C and Michel MS: Experimental models for therapeutic studies of transitional cell carcinoma. Anticancer Res. 27:3163–3171. 2007.PubMed/NCBI
62	Oshinsky GS, Chen Y, Jarrett T, Anderson AE and Weiss GH: A model of bladder tumor xenografts in the nude rat. J Urol. 154:1925–1929. 1995. View Article : Google Scholar : PubMed/NCBI
63	Watanabe T, Shinohara N, Sazawa A, et al: An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther. 7:1575–1580. 2000. View Article : Google Scholar : PubMed/NCBI
64	Asanuma H, Arai T, Seguchi K, et al: Successful diagnosis of orthotopic rat superficial bladder tumor model by ultrathin cystoscopy. J Urol. 169:718–720. 2003. View Article : Google Scholar : PubMed/NCBI
65	Hendricksen K, Molkenboer-Kuenen J, Oosterwijk E, Hulsbergen-van de Kaa CA and Witjes JA: Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy. BJU Int. 101:889–893. 2008. View Article : Google Scholar : PubMed/NCBI
66	Nokes B, Apel M, Jones C, Brown G and Lang JE: Aminolevulinic acid (ALA): photodynamic detection and potential therapeutic applications. J Surg Res. 181:262–271. 2013. View Article : Google Scholar : PubMed/NCBI
67	Satoh H, Morimoto Y, Arai T, et al: Intravesical ultrasonography for tumor staging in an orthotopically implanted rat model of bladder cancer. J Urol. 177:1169–1173. 2007. View Article : Google Scholar : PubMed/NCBI
68	Chin J, Kadhim S, Garcia B, Kim YS and Karlik S: Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J Urol. 145:1297–1301. 1991.PubMed/NCBI
69	Kikuchi E, Xu S, Ohori M, et al: Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging. J Urol. 170:1375–1378. 2003. View Article : Google Scholar : PubMed/NCBI
70	Becci PJ, Thompson HJ, Strum JM, Brown CC, Sporn MB and Moon RC: N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids. Cancer Res. 41:927–932. 1981.PubMed/NCBI
71	Cohen SM and Johansson SL: Epidemiology and etiology of bladder cancer. Urol Clin North Am. 19:421–428. 1992.PubMed/NCBI
72	Yamagiwa K and Ichikawa K: Experimental study of the pathogenesis of carcinoma. CA Cancer J Clin. 27:174–181. 1977. View Article : Google Scholar : PubMed/NCBI
73	Hueper WC, Wiley FH, Wolfe HD, et al: Experimental production of bladder tumors in dogs by administration of beta-naphthylamine. J Ind Hyg Toxicol. 20:46–84. 1938.
74	Armstrong EC and Bonser GM: Epithelial tumours of the urinary bladder in mice induced by 2-acetylamino-fluorine. J Pathol. 6:506–512. 1944.
75	Schalken JA, van Moorselaar RJ, Bringuier PP and Debruyne FM: Critical review of the models to study the biologic progression of bladder cancer. Semin Surg Oncol. 8:274–278. 1992. View Article : Google Scholar : PubMed/NCBI
76	Oliveira PA, Colaco A, De la Cruz PLF and Lopes C: Experimental bladder carcinogenesis-rodent models. Exp Oncol. 28:2–11. 2006.PubMed/NCBI
77	Clayson DB and Cooper EH: Cancer of the urinary tract. Adv Cancer Res. 13:271–381. 1970. View Article : Google Scholar
78	Fukushima S: Modification of tumor development in the urinary bladder. Prog Exp Tumor Res. 33:154–174. 1991.PubMed/NCBI
79	Kunze E and Chowaniec J: Pathology of tumours in laboratory animals Tumours of the rat Tumours of the urinary bladder. IARC Sci Publ. 345–397. 1990.PubMed/NCBI
80	Oliveira PA, Palmeira C, Lourenço LM and Lopes CA: Evaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. J Exp Clin Cancer Res. 24:609–616. 2005.PubMed/NCBI
81	Lu Y, Liu P, Wen W, et al: Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models. Am J Transl Res. 3:8–27. 2010.PubMed/NCBI
82	Cauvin JM, Goldfain D, Le Rhun M, et al: Multicentre prospective controlled study of Barrett’s oesophagus and colorectal adenomas. Groupe d’Etude de l’Oesophage de Barrett. Lancet. 346:1391–1394. 1995.
83	Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC and Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 82:1364–1369. 2000.PubMed/NCBI
84	Grubbs CJ, Lubet RA, Koki AT, et al: Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60:5599–5602. 2000.PubMed/NCBI
85	Steele VE, Rao CV, Zhang Y, et al: Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res (Phila). 2:951–956. 2009. View Article : Google Scholar : PubMed/NCBI
86	Lubet RA, Huebner K, Fong LY, et al: 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin. Carcinogenesis. 26:571–578. 2005. View Article : Google Scholar
87	Okajima E, Denda A, Ozono S, et al: Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 58:3028–3031. 1998.PubMed/NCBI
88	Hattori K, Iida K, Joraku A, Tsukamoto S, Akaza H and Oyasu R: Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int. 97:640–643. 2006. View Article : Google Scholar : PubMed/NCBI
89	D’Arca D, LeNoir J, Wildemore B, et al: Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor. Urol Oncol. 28:189–194. 2010.PubMed/NCBI
90	Ozawa A, Tanji N, Kikugawa T, et al: Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int. 105:1181–1186. 2010. View Article : Google Scholar : PubMed/NCBI
91	Ding Y, Paonessa JD, Randall KL, et al: Sulforaphane inhibits 4-aminobiphenyl-induced DNA damage in bladder cells and tissues. Carcinogenesis. 31:1999–2003. 2010. View Article : Google Scholar : PubMed/NCBI
92	Parada B, Reis F, Figueiredo A, et al: Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU Int. 107:135–143. 2011. View Article : Google Scholar : PubMed/NCBI
93	Parada B, Reis F, Pinto A, et al: Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. Int J Mol Sci. 13:8482–8499. 2012. View Article : Google Scholar
94	Sagara Y, Miyata Y, Nomata K, Hayashi T and Kanetake H: Green tea polyphenol suppresses tumor invasion and angiogenesis in N-butyl-(−4-hydroxybutyl) nitrosamine-induced bladder cancer. Cancer Epidemiol. 34:350–354. 2010.PubMed/NCBI
95	Prasain JK, Jones K, Moore R, et al: Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers. Oncol Rep. 19:1565–1570. 2008.PubMed/NCBI
96	Zhang G, Zeng X, Li C, et al: Inhibition of urinary bladder carcinogenesis by aqueous extract of sclerotia of Polyporus umbellatus fries and polyporus polysaccharide. Am J Chin Med. 39:135–144. 2011. View Article : Google Scholar : PubMed/NCBI
97	Munday R, Mhawech-Fauceglia P, Munday CM, et al: Inhibition of urinary bladder carcinogenesis by broccoli sprouts. Cancer Res. 68:1593–1600. 2008. View Article : Google Scholar : PubMed/NCBI
98	Kunze E, Schulz H, Adamek M and Gabius HJ: Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N- (4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response. J Cancer Res Clin Oncol. 126:125–138. 2000. View Article : Google Scholar
99	Fukushima S, Hirose M, Tsuda H, Shirai T and Hirao K: Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gann. 67:81–90. 1976.PubMed/NCBI
100	Becci PJ, Thompson HJ, Strum JM, et al: N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids. Cancer Res. 41:927–932. 1981.PubMed/NCBI
101	Herman CJ, Vegt PD, Debruyne FM, Vooijs GP and Ramaekers FC: Squamous and transitional elements in rat bladder carcinomas induced by N-butyl-N-4-hydroxybutyl-nitrosamine (BBN). A study of cytokeratin expression. Am J Pathol. 120:419–426. 1985.PubMed/NCBI
102	Hicks RM and Wakefield JS: Rapid induction of bladder cancer in rats with N-methyl-N-nitrosourea. I. Histology. Chem Biol Interact. 5:139–152. 1972. View Article : Google Scholar : PubMed/NCBI
103	Steinberg GD, Brendler CB, Ichikawa T, Squire RA and Isaacs JT: Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res. 50:6668–6674. 1990.PubMed/NCBI
104	Russo J, Russo IH, Rogers AE, van Zwieten MJ and Gusterson B: Pathology of tumours in laboratory animals Tumours of the rat Tumours of the mammary gland. IARC Sci Publ. 47–78. 1990.PubMed/NCBI
105	Wu JT, Han BM, Yu SQ, Wang HP and Xia SJ: Androgen receptor is a potential therapeutic target for bladder cancer. Urology. 75:820–827. 2010. View Article : Google Scholar : PubMed/NCBI
106	Li Y, Zheng Y, Izumi K, et al: Androgen activates beta-catenin signaling in bladder cancer cells. Endocr Relat Cancer. 20:293–304. 2013. View Article : Google Scholar : PubMed/NCBI
107	Kunze E, Graewe T, Scherber S, Weber J and Gellhar P: Cell cycle dependence of N-methyl-N-nitrosourea-induced tumour development in the proliferating, partially resected rat urinary bladder. Br J Exp Pathol. 70:125–142. 1989.PubMed/NCBI
108	Tian B, Wang Z, Zhao Y, et al: Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett. 264:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
109	Fragoso MF, Prado MG, Barbosa L, Rocha NS and Barbisan LF: Inhibition of mouse urinary bladder carcinogenesis by açai fruit (Euterpe oleraceae Martius) intake. Plant Foods Hum Nutr. 67:235–241. 2012.
110	Bidinotto LT, Spinardi-Barbisan AL, Rocha NS, Salvadori DM and Barbisan LF: Effects of ginger (Zingiber officinale Roscoe) on DNA damage and development of urothelial tumors in a mouse bladder carcinogenesis model. Environ Mol Mutagen. 47:624–630. 2006. View Article : Google Scholar
111	Jaenisch R and Mintz B: Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc Natl Acad Sci USA. 71:1250–1254. 1974. View Article : Google Scholar : PubMed/NCBI
112	Hanahan D, Wagner EF and Palmiter RD: The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 21:2258–2270. 2007. View Article : Google Scholar : PubMed/NCBI
113	Lin JH, Zhao H and Sun TT: A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proc Natl Acad Sci USA. 92:679–683. 1995. View Article : Google Scholar : PubMed/NCBI
114	Zhang ZT, Pak J, Shapiro E, Sun TT and Wu XR: Urothelium- specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 59:3512–3517. 1999.PubMed/NCBI
115	Grippo PJ and Sandgren EP: Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am J Pathol. 157:805–813. 2000. View Article : Google Scholar : PubMed/NCBI
116	Koss LG: Bladder cancer from a perspective of 40 years. J Cell Biochem Suppl. 16I:23–29. 1992.PubMed/NCBI
117	Zhang ZT, Pak J, Huang HY, et al: Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 20:1973–1980. 2001. View Article : Google Scholar : PubMed/NCBI
118	Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF and Knowles MA: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 24:5218–5225. 2005. View Article : Google Scholar : PubMed/NCBI
119	Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH and Zwarthoff EC: FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 5:e138212010. View Article : Google Scholar : PubMed/NCBI
120	Cheng J, Huang H, Zhang ZT, et al: Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res. 62:4157–4163. 2002.PubMed/NCBI
121	Lindgren D, Liedberg F, Andersson A, et al: Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 25:2685–2696. 2006. View Article : Google Scholar : PubMed/NCBI
122	Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al: Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23:675–680. 2009. View Article : Google Scholar : PubMed/NCBI
123	Ayala de la Peña F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G and Kalluri R: Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem. 286:20778–20787. 2011.PubMed/NCBI
124	Ho PL, Lay EJ, Jian W, Parra D and Chan KS: Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 72:3135–3142. 2012. View Article : Google Scholar : PubMed/NCBI
125	Ogawa K, Murasaki T, Sugiura S, Nakanishi M and Shirai T: Organ differences in the impact of p27(kip1) deficiency on carcinogenesis induced by N-methyl-N-nitrosourea. J Appl Toxicol. 33:471–479. 2013. View Article : Google Scholar : PubMed/NCBI
126	Baffa R, Fassan M, Sevignani C, et al: Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis. Carcinogenesis. 29:846–848. 2008. View Article : Google Scholar : PubMed/NCBI
127	Slocum SL and Kensler TW: Nrf2: control of sensitivity to carcinogens. Arch Toxicol. 85:273–284. 2011. View Article : Google Scholar : PubMed/NCBI
128	Fukushima S, Friedell GH, Jacobs JB and Cohen SM: Effect of L-tryptophan and sodium saccharin on urinary tract carcinogenesis initiated by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. Cancer Res. 41:3100–3103. 1981.
129	Gibbs RA, Weinstock GM, Metzker ML, et al; Rat Genome Sequencing Project Consortium. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature. 428:493–521. 2004. View Article : Google Scholar : PubMed/NCBI
130	Mouse Genome Sequencing Consortium. Waterston RH, Lindblad-Toh K, et al: Initial sequencing and comparative analysis of the mouse genome. Nature. 420:520–562. 2002. View Article : Google Scholar : PubMed/NCBI
131	Kitada K, Ishishita S, Tosaka K, et al: Transposon-tagged mutagenesis in the rat. Nat Methods. 4:131–133. 2007. View Article : Google Scholar : PubMed/NCBI
132	Geurts AM, Cost GJ, Freyvert Y, et al: Knockout rats via embryo microinjection of zinc-finger nucleases. Science. 325:4332009. View Article : Google Scholar : PubMed/NCBI
133	Corpet DE and Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer. 41:1911–1922. 2005. View Article : Google Scholar : PubMed/NCBI
134	Zeng J, Sun Y, Wu K, et al: Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther. 10:104–116. 2011. View Article : Google Scholar : PubMed/NCBI